Abstract
Recent advances have identified novel small molecule inhibitors of the transforming growth factor-beta (TGF-beta) type I receptor kinase as a potential therapy in organ remodeling diseases, such as chronic renal disease. Because TGF-beta is central to the progression of fibrosis, selective inhibition of this signaling pathway could provide a novel treatment in many fibrotic diseases. The rationale for inhibition of TGF-beta signaling in renal disease includes prevention of fibrosis, tubular dedifferentiation and vascular effects.
MeSH terms
-
Activin Receptors, Type I / antagonists & inhibitors*
-
Activin Receptors, Type I / physiology*
-
Animals
-
Humans
-
Kidney Diseases / drug therapy
-
Kidney Diseases / metabolism*
-
Protein Serine-Threonine Kinases
-
Receptor, Transforming Growth Factor-beta Type I
-
Receptors, Transforming Growth Factor beta / antagonists & inhibitors*
-
Receptors, Transforming Growth Factor beta / physiology*
-
Signal Transduction / drug effects
-
Signal Transduction / physiology
Substances
-
Receptors, Transforming Growth Factor beta
-
Protein Serine-Threonine Kinases
-
Activin Receptors, Type I
-
Receptor, Transforming Growth Factor-beta Type I
-
TGFBR1 protein, human